Shares of Eidos Therapeutics Inc (NASDAQ:EIDX) have earned a consensus rating of “Buy” from the nine ratings firms that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $28.50.
Several research analysts have recently issued reports on the company. BTIG Research assumed coverage on Eidos Therapeutics in a research note on Wednesday, April 17th. They set a “buy” rating and a $38.00 price target for the company. Zacks Investment Research downgraded Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. BMO Capital Markets assumed coverage on Eidos Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $28.00 price target for the company. Finally, JPMorgan Chase & Co. downgraded Eidos Therapeutics from an “overweight” rating to a “neutral” rating and set a $29.00 price target for the company. in a research note on Wednesday, January 23rd.
In other news, CFO Christine Siu sold 5,000 shares of Eidos Therapeutics stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $26.11, for a total transaction of $130,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 21,913 shares of company stock valued at $480,310 in the last ninety days.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in Eidos Therapeutics by 57.9% in the 4th quarter. BlackRock Inc. now owns 1,149,364 shares of the company’s stock valued at $15,814,000 after purchasing an additional 421,666 shares during the last quarter. Aisling Capital Management LP acquired a new position in Eidos Therapeutics in the 4th quarter valued at about $15,461,000. Victory Capital Management Inc. acquired a new position in Eidos Therapeutics in the 4th quarter valued at about $2,835,000. Vanguard Group Inc. raised its stake in Eidos Therapeutics by 297.3% in the 3rd quarter. Vanguard Group Inc. now owns 198,673 shares of the company’s stock valued at $1,983,000 after purchasing an additional 148,673 shares during the last quarter. Finally, Vanguard Group Inc raised its stake in Eidos Therapeutics by 297.3% in the 3rd quarter. Vanguard Group Inc now owns 198,673 shares of the company’s stock valued at $1,983,000 after purchasing an additional 148,673 shares during the last quarter. 30.15% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ EIDX opened at $26.02 on Friday. The firm has a market cap of $958.03 million and a price-to-earnings ratio of -13.99. Eidos Therapeutics has a one year low of $8.89 and a one year high of $29.74.
Eidos Therapeutics (NASDAQ:EIDX) last released its quarterly earnings results on Monday, April 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.01). As a group, sell-side analysts predict that Eidos Therapeutics will post -1.52 earnings per share for the current fiscal year.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Recommended Story: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.